Table 4.
Dynamic changes in ELISPOT patterns in twenty seven patients with viable and interpretable enrolment samples and at least two viable and interpretable samples at or beyond end of phase 2.
| ELISPOT patterns at or beyond end phase 2 | |||
|---|---|---|---|
| No response OR CD25+/CD19+ regulated anti-donor response | B-dependent anti-donor response—no evidence of regulation* | ||
| Pre-end phase 2 | Any ELISPOT pattern |
N = 21 (4)† Median ΔeGFR−9.41 (IQR 9.5)∅ |
N = 6 (3) Median ΔeGFR−20.55 (IQR 7.8)ø |
*
Only includes patients with enrolment and 2 or more viable and interpretable post treatment ELISPOTs. If any of these ELISPOTs showed evidence of non-regulated B-dependent anti-donor IFNγ production, the patient is included in one of these two columns.
†
Numbers in parentheses indicate the number with failed grafts or withdrawals due to IS reduction as a prelude to starting dialysis.
ø
Comparison of median ΔeGFR at 3 years: p = 0.02 by Mann Whittney U.
Refer to Supplementary Table 7 to see the individual ELISPOTs from all 27 patients included in this table.